• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.82% Nasdaq Up0.70%

    Alnylam Pharmaceuticals, Inc. (ALNY)

    -NasdaqGS
    63.55 Up 5.74(9.93%) May 25, 4:00PM EDT
    Income StatementGet Income Statement for:
    View: Annual Data | Quarterly DataAll numbers in thousands
    Period EndingDec 31, 2015Dec 31, 2014Dec 31, 2013
    Total Revenue 41,097   50,561   47,167  
    Cost of Revenue -   -   -  
    Gross Profit 41,097   50,561   47,167  
    Operating Expenses
    Research Development276,495  190,249  112,957  
    Selling General and Administrative60,610  44,526  27,152  
    Non Recurring -  220,766   -  
    Others -   -   -  
    Total Operating Expenses -   -   -  
    Operating Income or Loss (296,008) (404,980) (92,942)
    Income from Continuing Operations
    Total Other Income/Expenses Net5,935  4,376  1,022  
    Earnings Before Interest And Taxes(290,073)(400,604)(91,920)
    Interest Expense -   -   -  
    Income Before Tax(290,073)(400,604)(91,920)
    Income Tax Expense -  (40,209)(2,695)
    Minority Interest -   -   -  
    Net Income From Continuing Ops(290,073)(360,395)(89,225)
    Non-recurring Events
    Discontinued Operations -   -   -  
    Extraordinary Items -   -   -  
    Effect Of Accounting Changes -   -   -  
    Other Items -   -   -  
    Net Income (290,073) (360,395) (89,225)
    Preferred Stock And Other Adjustments -   -   -  
    Net Income Applicable To Common Shares (290,073) (360,395) (89,225)

    Sign Up for a Free Trial to EDGAR Online Premium!
    Get the critical business and financial information you need for more than 15,000 U.S. public companies.
    Sign Up Now - Learn More

    Currency in USD.